Price Target Changed • Aug 15
Price target decreased by 88% to US$17.00 Down from US$142, the current price target is provided by 1 analyst. New target price is 3,909% above last closing price of US$0.42. Stock is down 94% over the past year. The company is forecast to post a net loss per share of US$2.18 next year compared to a net loss per share of US$7.18 last year. お知らせ • May 31
Aceragen Receives Nasdaq Notice Regarding Delayed Form 10-Q Filing Aceragen, Inc. announced that on May 24, 2023, the Company received a notice from The Nasdaq Stock Market LLC (“Nasdaq”) stating that because the Company had not yet filed its Quarterly Report on Form 10-Q for the quarterly period ended March 31, 2023 (the “Form 10-Q”), the Company is not in compliance with Nasdaq Listing Rule 5250(c)(1), which requires timely filing of periodic financial reports with the Securities and Exchange Commission. The Nasdaq notice has no immediate effect on the listing or trading of the Company’s common stock on The Nasdaq Global Market. The Company has until July 24, 2023 to submit to Nasdaq a plan to regain compliance. If Nasdaq accepts the Company’s plan, then Nasdaq may grant the Company up to 180 calendar days from the Form 10-Q’s original due date, or November 20, 2023, to regain compliance. If the Company is unable to make such filings by July 24, 2023, the Company intends to submit to Nasdaq a plan to regain compliance. お知らせ • May 16
Aceragen, Inc. announced delayed 10-Q filing On 05/15/2023, Aceragen, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC. お知らせ • May 06
Aceragen, Inc. Announces John Kirby No Longer Serves as Chief Financial Officer Aceragen, Inc. announced that effective as of the Effective Date, John Kirby no longer serves as the Company’s Chief Financial Officer or is employed by the Company. Mr. Kirby is entitled to certain payments and post-termination benefits as set forth in his employment continuation and retention bonus letter agreement and his Severance and Change of Control Agreement with the Company, each as described on pages 80, 88 and 89 of the 2022 Form 10-K. お知らせ • Feb 07
Aceragen, Inc. Announces Recommendation of Data Monitoring Committee in Terra Study Aceragen, Inc. announced the recommendation of its independent Data Monitoring Committee (DMC) in regard to the on-going TERRA Phase 2 study of ACG-701 in patients with melioidosis. The DMC is responsible for providing oversight of safety and efficacy for this study and has recommended the TERRA study continue without modification. The DMC review was a planned meeting held in order to monitor the safety of the seriously ill subjects participating in the TERRA study. Aceragen has executed an ~$50 million development partnership with the Department of Defense’s Defense Threat Reduction Agency (“DTRA”) to investigate ACG-701 as a potential medical countermeasure for melioidosis, a life-threatening infection caused by the B. pseudomallei pathogen. This program is centered around a Phase 2 trial, the TERRA study (NCT05105035), which is a randomized double-blind, placebo-controlled trial conducted in hospitalized melioidosis patients. TERRA was initiated in May 2022 and continues to actively enroll patients with a data read-out expected in the fourth quarter of 2023. お知らせ • Feb 04
Aceragen, Inc. Announces Bryant D. Lim to Leave as Senior Vice President, Chief Business Officer and General Counsel of the Company, Effective February 17, 2023 Aceragen, Inc. announced that on February 3, 2023, Bryant D. Lim will be leaving his role as Senior Vice President, Chief Business Officer and General Counsel of the Company, effective February 17, 2023, to pursue another opportunity. Board Change • Jun 01
Insufficient new directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 5 experienced directors. 2 highly experienced directors. Independent Chairman Mike Dougherty was the last director to join the board, commencing their role in 2019. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model. Board Change • May 02
Insufficient new directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 5 experienced directors. 2 highly experienced directors. Independent Chairman Mike Dougherty was the last director to join the board, commencing their role in 2019. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model. Director Overboarding • Aug 03
Director Vincent Milano has joined 3rd company board President, CEO & Director Vincent Milano has been appointed to the board of BioCryst Pharmaceuticals, Inc. (NasdaqGS:BCRX). Milano now sits on a total of 3 company boards. With 3 board positions including the role of CEO at Idera Pharmaceuticals, Inc. (NasdaqCM:IDRA), the director is at risk of having too many board obligations according to the Simply Wall St Risk Model. Director Overboarding • Aug 03
Director Vincent Milano has joined 3rd company board President, CEO & Director Vincent Milano has been appointed to the board of BioCryst Pharmaceuticals, Inc. (NasdaqGS:BCRX). Milano now sits on a total of 3 company boards. With 3 board positions including the role of CEO at Idera Pharmaceuticals, Inc. (NasdaqCM:IDRA), the director is at risk of having too many board obligations according to the Simply Wall St Risk Model. Director Overboarding • Aug 03
Director Vincent Milano has joined 3rd company board President, CEO & Director Vincent Milano has been appointed to the board of BioCryst Pharmaceuticals, Inc. (NasdaqGS:BCRX). Milano now sits on a total of 3 company boards. With 3 board positions including the role of CEO at Idera Pharmaceuticals, Inc. (NasdaqCM:IDRA), the director is at risk of having too many board obligations according to the Simply Wall St Risk Model. Recent Insider Transactions • Jun 22
Senior VP & COO recently bought US$60k worth of stock On the 18th of June, Daniel Soland bought around 50k shares on-market at roughly US$1.19 per share. In the last 3 months, there was an even bigger purchase from another insider worth US$101k. Daniel has been a buyer over the last 12 months, purchasing a net total of US$98k worth in shares. Recent Insider Transactions • Jun 04
Independent Chairman recently bought US$101k worth of stock On the 1st of June, Michael Dougherty bought around 85k shares on-market at roughly US$1.19 per share. This was the largest purchase by an insider in the last 3 months. This was Michael's only on-market trade for the last 12 months. Executive Departure • May 30
Senior VP & Chief Medical Officer has left the company On the 28th of May, Elizabeth Tarka's tenure as Senior VP & Chief Medical Officer ended after 1.8 years in the role. As of March 2021, Elizabeth personally held only 13.24k shares (US$17k worth at the time). Elizabeth is the only executive to leave the company over the last 12 months. Price Target Changed • Mar 16
Price target increased to US$8.60 Up from US$7.83, the current price target is an average from 4 analysts. New target price is 84% above last closing price of US$4.68. Stock is up 337% over the past year. Is New 90 Day High Low • Jan 20
New 90-day high: US$5.40 The company is up 158% from its price of US$2.09 on 21 October 2020. The American market is up 13% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Biotechs industry, which is up 22% over the same period. Recent Insider Transactions • Dec 26
President recently sold US$161k worth of stock On the 22nd of December, Vincent Milano sold around 37k shares on-market at roughly US$4.32 per share. This was the largest sale by an insider in the last 3 months. This was Vincent's only on-market trade for the last 12 months. Recent Insider Transactions Derivative • Dec 26
President notifies of intention to sell stock Vincent Milano intends to sell roughly 37.17k shares in the next 90 days after lodging an Intent To Sell Form on the 22nd of December. If the sale is conducted around the recent share price of US$4.41, it would amount to US$164k. For the year to December 2019, Vincent's total compensation was 45% salary and 55% non-salary (Indicating these sales could comprise a meaningful part of their income for the year). Since March 2020, Vincent has owned 61.25k shares directly. This was the only transaction from an insider over the last 12 months. Is New 90 Day High Low • Nov 19
New 90-day high: US$3.33 The company is up 84% from its price of US$1.81 on 20 August 2020. The American market is up 7.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Biotechs industry, which is up 5.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is per share. Analyst Estimate Surprise Post Earnings • Nov 03
Earnings beat expectations Revenue was in line with analyst estimates. Earnings per share (EPS) surpassed analyst estimates by 168%. Is New 90 Day High Low • Oct 29
New 90-day high: US$2.69 The company is up 35% from its price of US$1.99 on 30 July 2020. The American market is up 2.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Biotechs industry, which is down 3.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is per share. Is New 90 Day High Low • Sep 19
New 90-day high: US$2.68 The company is up 41% from its price of US$1.90 on 19 June 2020. The American market is up 9.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Biotechs industry, which is down 2.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is per share.